TY - JOUR
T1 - Antiplatelet therapy for recurrent stroke prevention
T2 - newer perspectives based on (MATCH), (CHARISMA), and (ESPRIT)
AU - Gorelick, Philip B.
PY - 2008/1
Y1 - 2008/1
N2 - Antiplatelet therapy is an important component of our armamentarium for recurrent stroke prevention. Aspirin is a safe and effective antiplatelet drug for recurrent stroke prevention, however, it has been challenged recently by the thienopyridine derivative, clopidogrel, and the combination agent, aspirin plus extended release dipyridamole. In this review, we discuss recent studies of thienopyridine derivatives and aspirin plus extended-release dipyridamole in stroke prevention and evidence-based guidelines for the administration of these agents in practice for recurrent stroke prevention.
AB - Antiplatelet therapy is an important component of our armamentarium for recurrent stroke prevention. Aspirin is a safe and effective antiplatelet drug for recurrent stroke prevention, however, it has been challenged recently by the thienopyridine derivative, clopidogrel, and the combination agent, aspirin plus extended release dipyridamole. In this review, we discuss recent studies of thienopyridine derivatives and aspirin plus extended-release dipyridamole in stroke prevention and evidence-based guidelines for the administration of these agents in practice for recurrent stroke prevention.
KW - Antiplatelet therapy
KW - recurrent stroke prevention
UR - http://www.scopus.com/inward/record.url?scp=38349087029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349087029&partnerID=8YFLogxK
U2 - 10.1016/j.jash.2007.07.003
DO - 10.1016/j.jash.2007.07.003
M3 - Review article
C2 - 20409878
AN - SCOPUS:38349087029
SN - 1933-1711
VL - 2
SP - 3
EP - 7
JO - Journal of the American Society of Hypertension
JF - Journal of the American Society of Hypertension
IS - 1
ER -